Union Minister Piyush Goyal held a meeting with stakeholders from India's pharmaceutical industry to discuss the future of the sector amid potential US tariffs on pharmaceutical imports. The discussions focused on enhancing regulatory frameworks and accelerating growth within the industry. Goyal highlighted the government's commitment to developing a future-ready, innovation-driven pharma sector that can attract high-quality investments and improve global competitiveness. The meeting is particularly relevant as the US considers imposing tariffs on imported pharmaceutical products, which could impact global trade dynamics. However, Indian industry representatives believe that the proposed tariffs will not significantly affect exports, especially since India's pharmaceutical exports mainly consist of generic drugs and active pharmaceutical ingredients, which are not covered by the tariffs. The US remains a crucial market for Indian pharmaceuticals, accounting for a significant portion of exports.